The early impact of COVID-19 on the incidence, prevalence, and severity of alcohol use and other drugs: A systematic review
Standard
The early impact of COVID-19 on the incidence, prevalence, and severity of alcohol use and other drugs: A systematic review. / Schmidt, Rose A; Genois, Rosalie; Jin, Jonathan; Vigo, Daniel; Rehm, Jürgen; Rush, Brian.
in: DRUG ALCOHOL DEPEN, Jahrgang 228, 109065, 01.11.2021.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - The early impact of COVID-19 on the incidence, prevalence, and severity of alcohol use and other drugs: A systematic review
AU - Schmidt, Rose A
AU - Genois, Rosalie
AU - Jin, Jonathan
AU - Vigo, Daniel
AU - Rehm, Jürgen
AU - Rush, Brian
N1 - Copyright © 2021 Elsevier B.V. All rights reserved.
PY - 2021/11/1
Y1 - 2021/11/1
N2 - BACKGROUND: The aim of this paper was to examine the early impact of COVID-19 on substance use to assess implications for planning substance use treatment and support systems.METHOD: A systematic review of literature published up to March 2021 was conducted to summarize changes in prevalence, incidence, and severity of substance use associated with COVID-19 and the accompanying public health measures, including lockdown, stay-at-home orders, and social distancing.RESULTS: We identified 53 papers describing changes to substance use at the population level. The majority of papers described changes related to alcohol use and most relied on self-reported measures of consumption during the COVID-19 pandemic, compared with pre-pandemic use. There was less evidence to support changes in non-alcohol substance use. In general, risky pre-pandemic alcohol use, caregiving responsibilities, stress, depression, anxiety, and current treatment for a mental disorder were found to be associated with increased substance use.CONCLUSION: This review provides preliminary data on changes in substance use, indicating that certain segments of the population increased their alcohol use early on in the COVID-19 pandemic and may be at greater risk of harm and in need of additional services. There is a need for additional population-level information on substance use to inform evidence-based rapid responses from a treatment system perspective.
AB - BACKGROUND: The aim of this paper was to examine the early impact of COVID-19 on substance use to assess implications for planning substance use treatment and support systems.METHOD: A systematic review of literature published up to March 2021 was conducted to summarize changes in prevalence, incidence, and severity of substance use associated with COVID-19 and the accompanying public health measures, including lockdown, stay-at-home orders, and social distancing.RESULTS: We identified 53 papers describing changes to substance use at the population level. The majority of papers described changes related to alcohol use and most relied on self-reported measures of consumption during the COVID-19 pandemic, compared with pre-pandemic use. There was less evidence to support changes in non-alcohol substance use. In general, risky pre-pandemic alcohol use, caregiving responsibilities, stress, depression, anxiety, and current treatment for a mental disorder were found to be associated with increased substance use.CONCLUSION: This review provides preliminary data on changes in substance use, indicating that certain segments of the population increased their alcohol use early on in the COVID-19 pandemic and may be at greater risk of harm and in need of additional services. There is a need for additional population-level information on substance use to inform evidence-based rapid responses from a treatment system perspective.
KW - COVID-19
KW - Communicable Disease Control
KW - Humans
KW - Incidence
KW - Pandemics
KW - Pharmaceutical Preparations
KW - Prevalence
KW - SARS-CoV-2
U2 - 10.1016/j.drugalcdep.2021.109065
DO - 10.1016/j.drugalcdep.2021.109065
M3 - SCORING: Review article
C2 - 34600257
VL - 228
JO - DRUG ALCOHOL DEPEN
JF - DRUG ALCOHOL DEPEN
SN - 0376-8716
M1 - 109065
ER -